Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A case of small undifferentiated pancreatic carcinoma detected during follow-up for focal pancreatic parenchymal atrophy with fatty replacement.

Clinical journal of gastroenterology·2026

Same author

[Hematologic responses with favorable safety in three elderly patients with polycythemia vera treated with ropeginterferon alfa-2b].

[Rinsho ketsueki] The Japanese journal of clinical hematology·2026

Same author

Small Hepatoid Variant of Solid Pseudopapillary Neoplasm of the Pancreas: A Unique Case With Long-term Follow-up.

DEN open·2026

Same author

CAR-T cells with the CD38<sup>-</sup>CD73<sup>-</sup>Tim-3<sup>-</sup>HLA-DR<sup>+</sup> phenotype predict the efficacy of tisagenlecleucel as a treatment for B cell precursor ALL.

Cell reports. Medicine·2026

Same author

Large, White Globe Appearance-Like Endoscopic Findings: Stomach Lymphatic Invasion Distant From Advanced Gastric Cancer.

Journal of gastroenterology and hepatology·2026

Same author

Reduced dose and shorter duration venetoclax regimens are effective for newly diagnosed acute myeloid leukemia patients not considered fit for intensive treatment.

Leukemia & lymphoma·2025

Search research articles

Related Experiment Video

Updated: Jan 13, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Effective Treatment with Ruxolitinib and Ropeginterferon Alfa-2b for Refractory TAFRO-like Syndrome.

Satoko Oka¹, Yuina Ueda-Akagi¹, Takaya Mitsuyoshi¹

¹Division of Hematology, Japanese Red Cross Society Wakayama Medical Center, Japan.

Internal Medicine (Tokyo, Japan)

|October 29, 2025

Summary

TAFRO syndrome, a severe condition, may be treated by targeting the Janus kinase (JAK)/signal transducers and activators of transcription (STAT) pathway. Combination therapy with ruxolitinib and ropeginterferon alfa-2b shows promise for TAFRO-like syndrome.

Keywords:

JAK/STAT pathway TAFRO syndrome ropegIFNα2b ruxolitinib

More Related Videos

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

Related Experiment Videos

Last Updated: Jan 13, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

Area of Science:

Hematology
Immunology
Pharmacology

Background:

TAFRO syndrome is a rare, aggressive hematologic disorder characterized by multi-organ dysfunction and high fatality.
Current treatment options for TAFRO syndrome are limited, necessitating novel therapeutic strategies.
The Janus kinase (JAK)/signal transducers and activators of transcription (STAT) pathway is implicated in TAFRO syndrome pathogenesis.

Purpose of the Study:

To investigate the efficacy of combination therapy targeting the JAK/STAT pathway in a patient with TAFRO-like syndrome.
To report a successful treatment outcome in a refractory case of TAFRO-like syndrome.

Main Methods:

Treatment with a combination of ruxolitinib (a JAK inhibitor) and ropeginterferon alfa-2b.
Management of a patient with TAFRO-like syndrome and polycythemia vera (PV) with JAK2 V617F mutation refractory to prior therapies.

Main Results:

Successful treatment of TAFRO-like syndrome using the combination therapy.
Demonstrated efficacy in a patient with a complex history of PV refractory to multiple treatments.

Conclusions:

Targeting the JAK/STAT pathway with combination therapy, including ruxolitinib and ropeginterferon alfa-2b, offers a potential therapeutic approach for TAFRO-like syndrome.
This case highlights a successful treatment strategy for refractory TAFRO-like syndrome in the context of polycythemia vera.